Its expression has been previously shown to correlate with poor prognosis in ER+ breast cancer as a member of a validated, multivariate index assay combining five IHC antibodies in a prognostic test for Tamoxifen treated ER+ breast cancer [16,20]. The gene discussed is ESR1; the disease is breast cancer.